Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...14961497149814991500150115021503150415051506...15771578»
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Review, Journal:  An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. (Pubmed Central) -  Aug 26, 2017   
    Regorafenib is an oral multi-kinase inhibitor approved as a third-line therapy for advanced GIST and though its efficacy is limited in comparison to imatinib, it has activity across the various driver mutation categories in GIST even in the setting of imatinib resistance. Herein, we describe a case of central retinal vein occlusion (CRVO) secondary to regorafenib and review regorafenib's efficacy and toxicity profile.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Epigenetic controller, Metastases:  Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas (clinicaltrials.gov) -  Aug 24, 2017   
    P1/2,  N=47, Completed, 
    IORT is safe, with acceptable perioperative morbidity. Active, not recruiting --> Completed
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
    Enrollment open, Trial initiation date, Trial primary completion date, Metastases:  Trabectedin Maintenance Post 1st-line in STS (clinicaltrials.gov) -  Aug 24, 2017   
    P3,  N=90, Recruiting, 
    Not yet recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019
  • ||||||||||  imatinib / Generic mfg.
    Trial primary completion date:  Basket 1: Imatinib in Patients With Desmoid Tumor and Chondrosarcoma (clinicaltrials.gov) -  Aug 23, 2017   
    P2,  N=35, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, pomalidomide / Generic mfg.
    Journal:  Kaposi sarcoma herpesvirus-associated disorders and related diseases. (Pubmed Central) -  Aug 23, 2017   
    KSHV is the etiological agents of all forms of Kaposi sarcoma and several other diseases. Strategies employing immunomodulatory agents, cytokine inhibition, and targeting of KSHV-infected cells are areas of active research.
  • ||||||||||  Phase classification, Trial initiation date:  ETOILE: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors (clinicaltrials.gov) -  Aug 23, 2017   
    P=N/A,  N=250, Not yet recruiting, 
    Strategies employing immunomodulatory agents, cytokine inhibition, and targeting of KSHV-infected cells are areas of active research. Phase classification: P3 --> P=N/A | Initiation date: Nov 2016 --> Oct 2017
  • ||||||||||  Enrollment closed, Trial initiation date:  EPISObs: An Observational Study on Epithelioid Sarcoma (clinicaltrials.gov) -  Aug 23, 2017   
    P=N/A,  N=100, Active, not recruiting, 
    Phase classification: P3 --> P=N/A | Initiation date: Nov 2016 --> Oct 2017 Not yet recruiting --> Active, not recruiting | Initiation date: May 2017 --> Aug 2017
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
    Trial suspension, Myeloid-derived suppressor cells:  Dendritic Cell Vaccine for Children and Adults With Sarcoma (clinicaltrials.gov) -  Aug 22, 2017   
    P1,  N=56, Suspended, 
    We are currently enrolling patients in a multi-institutional registry to assess the utility of HD-IORT in high risk bladder cancer. Recruiting --> Suspended
  • ||||||||||  Votrient (pazopanib) / Novartis, Opdivo (nivolumab) / BMS
    Enrollment change, Trial withdrawal, Trial primary completion date, Metastases:  Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas (clinicaltrials.gov) -  Aug 22, 2017   
    P2,  N=0, Withdrawn, 
    Initiation date: Dec 2016 --> Nov 2017 | Trial primary completion date: Dec 2019 --> Nov 2020 N=79 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2020 --> Aug 2017
  • ||||||||||  Review, Journal:  Uterine Adenosarcoma: a Review. (Pubmed Central) -  Aug 19, 2017   
    The PIK3/AKT/PTEN pathway is mutated in ∼70 % of adenosarcomas, and this may represent a possible therapeutic target. This article reviews the current state of knowledge concerning uterine adenosarcoma and discusses the management of this rare tumor.
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
    Enrollment open, Enrollment change, Trial primary completion date:  Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (clinicaltrials.gov) -  Aug 17, 2017   
    P2,  N=64, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2014 Suspended --> Recruiting | N=90 --> 64 | Trial primary completion date: Jul 2017 --> Jun 2019
  • ||||||||||  IDC-G305 / Merck (MSD)
    Trial completion, Enrollment change, Trial primary completion date, Metastases:  A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (clinicaltrials.gov) -  Aug 17, 2017   
    P1,  N=13, Completed, 
    Suspended --> Recruiting | N=90 --> 64 | Trial primary completion date: Jul 2017 --> Jun 2019 Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Nov 2014 --> Dec 2016
  • ||||||||||  iC9-GD2-CAR-VZV-CTLs / Baylor College of Medicine
    Enrollment closed, Metastases:  VEGAS: iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (clinicaltrials.gov) -  Aug 16, 2017   
    P1,  N=26, Active, not recruiting, 
    Avoiding the use of adjuvant chemotherapy and radiotherapy in this low-risk patient population may decrease both short- and long-term morbidity and mortality. Recruiting --> Active, not recruiting
  • ||||||||||  New trial:  Rare CNS Tumors Outcomes &Risk (clinicaltrials.gov) -  Aug 15, 2017   
    P=N/A,  N=220, Recruiting, 
  • ||||||||||  Enrollment closed, Enrollment change, Metastases:  ?-TEA in Advanced Cancer (clinicaltrials.gov) -  Aug 10, 2017   
    P1,  N=17, Active, not recruiting, 
    Trial primary completion date: Jul 2017 --> Jul 2018 Recruiting --> Active, not recruiting | N=62 --> 17
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment closed, Trial primary completion date, Metastases:  Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) (clinicaltrials.gov) -  Aug 10, 2017   
    P1/2,  N=90, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=62 --> 17 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2018